Ying Wang

Ying Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
YZYanan Zhou
Yanan Zhou
DHDongni Hou
Dongni Hou
CCCuicui Chen
Cuicui Chen
YYYanping Yang
Yanping Yang
YWYing Wang
Ying Wang
YSYuanlin Song
Yuanlin Song
Background: The role of corticosteroids in acute respiratory distress syndrome (ARDS) remains contentious. This study aims to investigate the prognostic significance of immune deficiency in patients with ARDS and its response to varying doses of corticosteroids. Methods: This single-center, retrospective cohort study enrolled 657 ARDS patients from January 24, 2008, to September 12, 2022, at Zhongshan Hospital of Fudan University, Shanghai, China. The patients were categorized into a discovery dataset (n=357) and a validation dataset (n=300), based on admission date. Further validation of the results in the validation dataset was used to enhance the credibility of the study conclusions. The study examined the association between immune deficiency and the patients’ clinical characteristics, treatment measures, and prognosis. The primary outcome was 28-day mortality post disease onset. Data analysis was conducted from June 15, 2023 to August 15, 2023. Results: The initial risk factor analysis in the discovery dataset was primarily based on the clinical characteristics, and the results suggested that immune deficiency likely impacted overall survival among patients receiving different doses of corticosteroid treatment. Multivariate analysis identified immune deficiency as an independent prognostic factor for overall survival in both the discovery and validation datasets. The final analysis revealed that patients with mild to moderate ARDS [discovery dataset: hazard ratio (HR) =1.719; 95% confidence interval (CI): 1.229–2.406; log-rank test P=0.001; validation dataset: HR =1.874; 95% CI: 1.238–2.837; log-rank test P=0.002] or severe ARDS (discovery dataset: HR =1.874; 95% CI: 1.007–3.488; log-rank test P=0.04; validation dataset: HR =1.698; 95% CI: 1.042–2.768; log-rank test P=0.03) with immune deficiency exhibited lower overall survival rates. Patients with mild to moderate ARDS and immune deficiency showed greater benefits from low-dose corticosteroid treatment (HR =0.409; 95% CI: 0.249–0.671; P<0.001 for interaction), whereas those with severe ARDS and immune deficiency benefitted from both low and high-dose treatments (low corticosteroid: HR =0.299; 95% CI: 0.136–0.654; high corticosteroid: HR =0.458; 95% CI: 0.214–0.981; P=0.005 for interaction). Conclusions: Immune deficiency is an independent risk factor in ARDS. Incorporating it into the disease severity grading system based on the Berlin criteria may enhance personalized treatment approaches for ARDS patients. These findings warrant further validation through prospective, large-scale, multicenter randomized controlled trials (RCTs).

26 February 2025 in Cellular Oncology
Verified
Journal Article
Open access
PDF file
JWJiajun Wang
Jiajun Wang
XXXianglai Xu
Xianglai Xu
YWYing Wang
Ying Wang
YZYanjun Zhu
Yanjun Zhu
Purpose Immune checkpoint plus tyrosine kinase inhibition (IO + TKI) has emerged as the first-line therapy in metastatic renal cell carcinoma (RCC), but no biomarker can predict its efficacy. Thymidine kinase 1 (TK1) is closely associated with immune evasion in tumors. Methods Metastatic RCC patients treated by IO + TKI were enrolled from two cohorts (ZS-MRCC, n = 45; Javelin-101, n = 726). High-risk localized RCC were also enrolled (ZS-HRRCC, n = 40). TK1 was assessed by RNA-sequencing in all cohorts, and the immune contexture was assessed by flow cytometry and immunohistochemistry. Results Higher TK1 expression was found in patients resistant to IO + TKI therapy (p = 0.025). High-TK1 group showed poor progression-free survival (PFS) in both the ZS-MRCC cohort (P = 0.008) and the Javelin-101 cohort (P = 0.036). By multivariate Cox regression, high-TK1 was determined as an independent factor for poor PFS (hazard ratio (HR) = 3.855, P = 0.002). High-TK1 expression was associated with decreased granzyme B+ CD8+ T cells (ρ=-0.22, P = 0.18), increased PD1+ CD4+ T cells (ρ = 0.33, P = 0.04), increased PDL1+ macrophages (ρ = 0.45, P < 0.001), and increased regulatory T cells (ρ = 0.35, P = 0.03). A novel random forest (RF) risk score was built by machine learning based on TK1 and immunologic parameters. Combined IO + TKI therapy surpassed sunitinib monotherapy in the low RF risk score group (HR = 0.158, P < 0.001), but was inferior to sunitinib in the high RF risk score group (HR, 2.195, P < 0.001). Conclusion High-TK1 expression could be a potential indicator for therapeutic resistance, poor PFS and immune evasion in metastatic RCC under IO + TKI therapy. The novel RF risk score may help stratify patients for IO + TKI therapy.

22 March 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
JWJiajun Wang
Jiajun Wang
JLJinglai Lin
Jinglai Lin
JWJiahao Wang
Jiahao Wang
YWYing Wang
Ying Wang
YZYanjun Zhu
Yanjun Zhu
JGJianming Guo
Jianming Guo
Background: Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) therapy is the first-line recommendation for advanced renal cell carcinoma (RCC), but no biomarker has been approved for it. Annexin A2 (ANXA2) can induce immune escape in tumors. Methods: Two independent cohorts of advanced RCC treated by IO + TKI were utilized for survival analysis (ZS-MRCC, n = 45; Javelin-101, n = 726). ANXA2 expression was determined by RNA-sequencing. The impact of ANXA2 on the tumor microenvironment was assessed by RNA-sequencing, flow cytometry and immunohistochemistry in two localized RCC datasets (ZS-HRRCC, n = 40; TCGA-KIRC, n = 530). Results: ANXA2 was upregulated in non-responders of IO + TKI therapy (p = 0.027). High-ANXA2 group showed poor progression-free survival (PFS) in both the ZS-MRCC cohort (HR, 2.348; 95% CI 1.084–5.085; P = 0.025) and the Javelin-101 cohort (HR, 1.472; 95% CI 1.043–2.077; P = 0.027). Multivariate Cox regression determined ANXA2 as an independent prognostic factor (HR, 2.619; 95% CI 1.194–5.746; P = 0.016). High-ANXA2 was correlated with decreased proportion of granzyme B+ CD8+ T cells (Spearman’s ρ = − 0.40, P = 0.01), and increased TIM-3+ (Spearman’s ρ = 0.43, P < 0.001) and CTLA4+ (Spearman’s ρ = 0.49, P < 0.001) tumor-infiltrating lymphocytes. A random forest (RF) score was further build by integrating ANXA2 and immune genes, which stratified patients who would benefit from IO + TKI therapy (low-RF score, IO + TKI vs TKI, HR = 0.453, 95% CI 0.328–0.626; high-RF score, IO + TKI vs TKI, HR = 0.877, 95% CI 0.661–1.165; interaction P = 0.003). Conclusions: Upregulated ANXA2 was associated with poor PFS and therapeutic resistance in RCC treated by IO + TKI therapy, and related with T cell exhaustion. The integrated RF score could stratify patients who would benefit from IO + TKI therapy.

1 September 2021
Verified
Journal Article
Closed access
XXXianglai Xu
Xianglai Xu
YWYing Wang
Ying Wang
ZSZhang Sihong
Zhang Sihong
JLJidong Lu
Jidong Lu
XZXiaoyu Zheng
Xiaoyu Zheng
JGJianming Guo
Jianming Guo
Purpose: Benign prostatic hyperplasia (BPH) significantly reduces the quality of life. However, the biological mechanisms of BPH development remain largely unknown. We aimed to investigate the essential genomic and immunogenic features in BPH. Materials and Methods: Transcriptome profiling and clinical data of BPH and normal prostate samples were acquired from GEO datasets. The discovery sets were composed of GSE119195, GSE7307, GSE101486, while the validation set was GSE132714. ESTIMATE and CIBERSORT were used to investigate the immunogenic features. Furthermore, transcriptional and weighted gene co-expression network analysis (WGCNA) was used for further analysis. Results: BPH samples presented a higher immune score. Meanwhile, CIBERSORT deconvolution revealed that BPH exists significantly abundant M2 Macrophages, follicular T helper cells, resting mast cells, and fewer plas-ma cells, activated CD4+ memory T cells, and activated mast cells. WGCNA analysis also revealed significantly enriched immune-related modules in BPH. Transcriptomic analysis identified SOCS3, IL6, C3, IGF1, NOTCH1, and VCAN as key regulators of immunogenic phenotype in BPH. Moreover, we generated an immunological gene signature for BPH, which worked well in the validation cohort. Conclusion: In our study, BPH samples exhibited a distinct immune infiltration pattern, represented by an im-munological gene signature. This genomic-based assessment model reveals the potential transcriptomic patterns during BPH development.

19 October 2023 in Research Square
Verified
Preprint
Open access
PDF file
YZYanan Zhou
Yanan Zhou
DHDongni Hou
Dongni Hou
CCCuicui Chen
Cuicui Chen
YYYanping Yang
Yanping Yang
YWYing Wang
Ying Wang
YSYuanlin Song
Yuanlin Song
Objective To investigate the prognostic significance of immune deficiency in ARDS and its response to different doses of corticosteroids. Methods The study enrolled 657 patients and they were divided into discovery dataset (n = 357) and validation dataset (n = 300) according to the time of admission, and the relationship between immune deficiency and prognosis and response to corticosteroid therapy in patients with different severity were also analyzed. Results Immune deficiency was an independent prognostic factor affecting overall survival. Analysis showed that patients with mild to moderate ARDS (Discovery dataset: HR 1.719; 95% CI 1.229–2.406; Validation dataset: HR 1.874; 95% CI 1.238–2.837) or severe ARDS (Discovery dataset: HR 1.874; 95% CI 1.007–3.488; Validation dataset: HR 1.698; 95% CI 1.042–2.768) with immune deficiency had lower overall survival. And mild to moderate ARDS with immune deficiency benefit better from low dose corticosteroids (HR 0.409; 95% CI 0.249–0.671), severe ARDS with immune deficiency benefit better from both low (HR 0.299; 95% CI 0.136–0.654) and high dose corticosteroid treatment (HR 0.458; 95% CI 0.214–0.981). Conclusions Immune deficiency was considered to be an independent risk factor in ARDS patients, and its inclusion in the disease severity grading system based on PaO2/FiO2 was conducive to promoting personalized medication for ARDS patients.